ESR1 and breast cancer: Tamoxifen, a selective modulator of the estrogen receptor, has been the focus of research and a treatment method for breast cancer for over 50 years and remains recommended as a standard therapy for estrogen receptor positive (ER+) breast cancer by the Clinical Pharmacogenetics Implementation Consortium [1].